618 related articles for article (PubMed ID: 22446627)
1. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
Levin AM; Bates DL; Ring AM; Krieg C; Lin JT; Su L; Moraga I; Raeber ME; Bowman GR; Novick P; Pande VS; Fathman CG; Boyman O; Garcia KC
Nature; 2012 Mar; 484(7395):529-33. PubMed ID: 22446627
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15.
Ring AM; Lin JX; Feng D; Mitra S; Rickert M; Bowman GR; Pande VS; Li P; Moraga I; Spolski R; Ozkan E; Leonard WJ; Garcia KC
Nat Immunol; 2012 Dec; 13(12):1187-95. PubMed ID: 23104097
[TBL] [Abstract][Full Text] [Related]
3. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Peraino JS; Zhang H; Rajasekera PV; Wei M; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2014 Mar; 405():57-66. PubMed ID: 24462799
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.
Mitra S; Ring AM; Amarnath S; Spangler JB; Li P; Ju W; Fischer S; Oh J; Spolski R; Weiskopf K; Kohrt H; Foley JE; Rajagopalan S; Long EO; Fowler DH; Waldmann TA; Garcia KC; Leonard WJ
Immunity; 2015 May; 42(5):826-38. PubMed ID: 25992859
[TBL] [Abstract][Full Text] [Related]
5. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.
Leong JW; Chase JM; Romee R; Schneider SE; Sullivan RP; Cooper MA; Fehniger TA
Biol Blood Marrow Transplant; 2014 Apr; 20(4):463-73. PubMed ID: 24434782
[TBL] [Abstract][Full Text] [Related]
6. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
7. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood.
Hodge S; Hodge G; Flower R; Han P
Scand J Immunol; 2000 Jan; 51(1):67-72. PubMed ID: 10632978
[TBL] [Abstract][Full Text] [Related]
8. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.
Spangler JB; Tomala J; Luca VC; Jude KM; Dong S; Ring AM; Votavova P; Pepper M; Kovar M; Garcia KC
Immunity; 2015 May; 42(5):815-25. PubMed ID: 25992858
[TBL] [Abstract][Full Text] [Related]
10. A novel human
Fernandez IZ; Baxter RM; Garcia-Perez JE; Vendrame E; Ranganath T; Kong DS; Lundquist K; Nguyen T; Ogolla S; Black J; Galambos C; Gumbart JC; Dawany N; Kelsen JR; de Zoeten EF; Quinones R; Eissa H; Verneris MR; Sullivan KE; Rochford R; Blish CA; Kedl RM; Dutmer CM; Hsieh EWY
J Exp Med; 2019 Jun; 216(6):1255-1267. PubMed ID: 31040184
[TBL] [Abstract][Full Text] [Related]
11. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4
Smith GA; Taunton J; Weiss A
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259099
[TBL] [Abstract][Full Text] [Related]
12. Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera.
Sogo T; Kawahara M; Tsumoto K; Kumagai I; Ueda H; Nagamune T
J Immunol Methods; 2008 Aug; 337(1):16-23. PubMed ID: 18589435
[TBL] [Abstract][Full Text] [Related]
13. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
14. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
15. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.
Meghnem D; Morisseau S; Frutoso M; Trillet K; Maillasson M; Barbieux I; Khaddage S; Leray I; Hildinger M; Quéméner A; Jacques Y; Mortier E
J Immunol; 2017 Jun; 198(12):4563-4568. PubMed ID: 28507024
[TBL] [Abstract][Full Text] [Related]
16. Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes.
Shatrova AN; Mityushova EV; Vassilieva IO; Aksenov ND; Zenin VV; Nikolsky NN; Marakhova II
PLoS One; 2016; 11(12):e0167215. PubMed ID: 27936140
[TBL] [Abstract][Full Text] [Related]
17. Implications for gene therapy-limiting expression of IL-2R gamma c delineate differences in signaling thresholds required for lymphocyte development and maintenance.
Orr SJ; Roessler S; Quigley L; Chan T; Ford JW; O'Connor GM; McVicar DW
J Immunol; 2010 Aug; 185(3):1393-403. PubMed ID: 20592278
[TBL] [Abstract][Full Text] [Related]
18. Induction of interleukin-2 receptor alpha (IL-2Ralpha) expression by interleukin-2: important role of the interleukin-2 receptor beta chain region between the two Stat5 docking sites.
Imbert V; Rezzonico R; Reichenbach P; Nabholz M
Eur Cytokine Netw; 2002; 13(3):331-9. PubMed ID: 12231477
[TBL] [Abstract][Full Text] [Related]
19. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells.
Liu DV; Maier LM; Hafler DA; Wittrup KD
J Immunother; 2009; 32(9):887-94. PubMed ID: 19816193
[TBL] [Abstract][Full Text] [Related]
20. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.
Wang X; Rickert M; Garcia KC
Science; 2005 Nov; 310(5751):1159-63. PubMed ID: 16293754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
